

Aaron “Changgun” Lee

lee.chan@northeastern.edu

(202) 280-0174

[linkedin.com/in/aaron-c-lee-040357191](https://www.linkedin.com/in/aaron-c-lee-040357191)

EDUCATION

- 05/2023 – 05/2024 **Doctor of Pharmacy Candidate 2024**
Bouvé College of Health Sciences, School of Pharmacy
Northeastern University | Boston, MA
- 09/2018 – 05/2023 **Bachelor of Science in Pharmacy Studies**
Bouvé College of Health Sciences, School of Pharmacy
Northeastern University | Boston, MA

INDUSTRY RELATED EXPERIENCES

- 08/2023 – 09/2023 **Scientific Communications Agency**
BGB Group, SCIO-SYNGE-NYC Team | New York City, NY
Preceptor: Mariam Elsabaawi, PharmD
- Presented case scenarios on rare disease patient and healthcare provider interactions and provided potential solutions to highlight the real-world challenges to medical strategy and scientific affairs team
 - Provided improvement strategies of Bristol Myers Squibb’s Mavacamten (Camzyos) for Expose hypertrophic cardiomyopathy (HCM) campaign by collaborating and presenting social media platforms used in pharmaceutical unbranded campaigns to Camzyos medical strategy team
 - Improved quality of medical materials through inspecting and updating Camzyos medical training material, Jardiance frequently asked questions document, and Novartis Global Content Adaptation Guidance to medical writers and directors
 - Performed publication review to analyze real-world data of the treatment patterns, guidelines, and key biomarkers of non-small cell lung cancer to medical director
- 05/2023 – 06/2023 **Drug Information Review and Assessment**
Institute for Clinical and Economic Review (ICER), Pharmaceutical Intelligence | Boston, MA
Preceptor: Maria M. Lowe, PharmD, BCPS; Max Lee, PharmD
- Provided insights of KarXT’s impact on schizophrenia and novel complement inhibitor’s impact on paroxysmal nocturnal hemoglobinuria by creating and delivering presentations and dossiers to Pharmaceutical Intelligence team, internal Clinical and Economic Research team, company leaders, and external clinical experts
 - Informed regulatory inquiries of FDA approval dates and market share by creating documents of evidence-based regulatory timeline history of exon skipping drugs, Amondys 45, Exondys 51, Viltepso, and Vyondys 53 to chief medical officer
 - Supported key discussion points and streamlined task procedures by summarizing reports of drug candidate modification meetings and topic surveillance articles to Pharmaceutical Intelligence team

RESEARCH EXPERIENCES

- 08/2023 – 09/2023 **What are Real-world Treatment Patterns and Outcomes for Patients with Non-small cell Lung Cancer?**
BGB Group | Virtual
- Performed medical inquiry response and reviewed recent publications on treatment guidelines and outcomes for both initial and subsequent therapies in non-small cell lung cancer treatments
 - Evaluated real-world patient data of initial and subsequent treatments and outcomes
 - Created document summarizing the results of the treatment patterns and outcomes of three publications
 - Communicated with medical director for validity checks, feedback, and further discussions
- 08/2023 – 09/2023 **Pharmaceutical Branded and Unbranded Campaigns**
BGB Group | Virtual
- Examined both healthcare professional-focused unbranded rare disease and branded drug campaign websites
 - Created document of the objective and advantages of multiple branded and unbranded campaign websites
 - Investigated the benefits, impact, and outcomes of unbranded campaigns that utilize novel social media platforms
 - Created presentation on the improvement suggestions of Bristol Myer Squibb's Expose HCM campaign utilizing social media platforms
- 05/2023 – 06/2023 **Overview of Paroxysmal Nocturnal Hemoglobinuria and Novel Treatments**
Institute for Clinical and Economic Review (ICER) | Boston, MA
- Conducted literary research on the disease overview of paroxysmal nocturnal hemoglobinuria (PNH), phase 3 clinical trial and expert comments of iptacopan, danicopan, and crovalimab
 - Categorized key research data of the disease and 3 treatments into a dossier
 - Created slide decks on the general overview and guideline of paroxysmal nocturnal hemoglobinuria
 - Performed quality checks of the presentation and dossier by communicating with the Pharmaceutical Intelligence director for feedback and updates
 - Presented the slide decks to the Pharmaceutical Intelligence, Clinical and Economic Research team, key external experts, and company leaders
- 05/2023 – 06/2023 **Value Assessment of KarXT for Schizophrenia**
Institute for Clinical and Economic Review (ICER) | Boston, MA
- Rephrased and provided additional research data on the general overview (definition, signs and symptoms, economic burden, diagnosis) of schizophrenia
 - Created slide decks on the general overview of schizophrenia
 - Communicated with the Pharmaceutical Intelligence manager and Economic research team researchers for feedback and updates on the slide decks
 - Presented the slide decks to the Pharmaceutical Intelligence, Clinical and Economic Research team, and company leaders

05/2023 – 05/2023

Regulatory Approval Timeline of Exon Skipping Therapies

Institute for Clinical and Economic Review (ICER) | Boston, MA

- Researched approval dates, confirmatory trial results, and market shares for Amondys 45, Exondys 51, Viltepso and Vyondys 53 using Biomedtracker, Clinicaltrials.gov, and Datamonitor
- Participated in FDA advisory committee meeting for Exondys 51 (SRP-9001) and analyzed pharmaceutical analyst comments and view on the likelihood of FDA approval of Exondys 51
- Compared regulatory timelines of Biomedtracker and Clinicaltrials.gov for phase 3 pivotal trial completion, initiation, and FDA submission date of each exon skipping drug
- Created summarized document of the findings to chief medical officer

LEADERSHIP EXPERIENCES

09/2020 – 12/2021

Northeastern University Pi Delta Psi Asian American Interest Cultural Fraternity, Alpha Alpha Chapter: Social and Wellness and Healthcare Chair

- Presented COVID-19 safety policy updates based on CDC guidelines to educate and track internal members understanding of COVID-19
- Initiated meetings with internal chairs and external cultural fraternity chairs to assure safety and updates for social and cultural events under COVID-19 settings

01/2020 – 01/2021

Northeastern University Peer Tutoring: General Biology and Chemistry Tutor

- Created summary notes and sample questions based on the student's needs in specific chapters of each section
- Provided feedback of student's improvements and progressions through analysis of exam questions and results

CLINICAL PROFESSIONAL EXPERIENCE

01/2021 – Present

Shriners Hospital for Children Boston | Boston, MA

Inpatient Pharmacy Intern

- Collaborated meetings and projects with pharmacy director and staffs such as monthly pharmacy meetings, interprofessional meetings, and pharmacy inventory projects.
- Educated new co-op and IPPE student's daily tasks and demonstrations in compounding steril and non-sterile products

06/2020 – 08/2020

Boston Medical Center | Boston, MA

Shapiro Outpatient Pharmacy Intern

- Dispensed medications and reconciled patients with insurance errors
- Input electronically processed and filled patient profiles and prescriptions
- Provided customer services through refill reminder calls and support with questions and concerns

OTHER EXTRACURRICULAR ACTIVITIES

2019 – 2019

Northeastern University American Pharmacists Organization (APhA): Smoking Cessation Awareness Campaign

- Addressed awareness of the risks of cigarettes and electronic cigarettes by researching the epidemiology and risk factors of smoking and communicating with university students
- Improved quality of poster and presentation by performing quality check reviews done by team members